Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/mto.2016.11 http://scihub22266oqcxt.onion/10.1038/mto.2016.11 C5008265!5008265!27626062     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27626062&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27626062.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Mol+Ther+Oncolytics 2016 ; 3 (ä): 16011- Nephropedia Template TP {{tp|p=27626062|t=2016. Toxicity and management in CAR T-cell therapy |pdf=|usr=}}{{27626062}} gab.com Text Toxicity and management in CAR T-cell therapy JO: Mol Ther Oncolytics http://www.kidney.de/pget.php?&tw=1&pmid=27626062 #FOAvip T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, ?on target/off tumor? recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management. Twit Text FOAVip Toxicity and management in CAR T-cell therapy ????Mol Ther Oncolytics http://www.kidney.de/pget.php?&tw=1&pmid=27626062 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27626062 #FOAvip English Wikipedia <ref>{{Cite pmid|27626062}}</ref> Toxicity and management in CAR T-cell therapy #MMPMID27626062 Bonifant CL; Jackson HJ; Brentjens RJ; Curran KJ Mol Ther Oncolytics 2016[]; 3 (ä): 16011- PMID27626062show ga T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, ?on target/off tumor? recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management. äToxicity and management in CAR T-cell therapy (epmc).pdf DeepDyve Pubget Overpricing